BPC-157 is a synthetic peptide made up of 15 amino acids, derived from a protective protein naturally found in human gastric (stomach) juice. Its full name, “body protective compound 157,” reflects what researchers first noticed about it: it appears to help the body repair damaged tissue. Despite growing popularity in fitness and wellness communities, BPC-157 is not an approved medication in any country. Nearly all evidence for its healing effects comes from animal studies, though the first human clinical trial is now underway.
Where BPC-157 Comes From
The peptide was originally isolated from human gastric juice in the early 1990s. Researchers identified a larger protein in the stomach that seemed to protect the gut lining, then synthesized a shorter, 15-amino-acid fragment that retained the protective activity. That fragment is what we call BPC-157, with a molecular weight of about 1,419 daltons, making it a very small peptide by biological standards.
Because it’s so small and relatively simple, BPC-157 can be manufactured through solid-phase synthesis, a standard laboratory technique for building peptides one amino acid at a time. Lab-produced versions can reach 99% purity. This is the form used in all research and in the supplements circulating online. Your body does not produce BPC-157 on its own in this exact form; it’s a fragment of a larger, naturally occurring stomach protein.
How It Works in the Body
BPC-157’s most studied effect is its ability to stimulate the growth of new blood vessels, a process called angiogenesis. It does this by boosting the activity of a receptor on blood vessel cells that responds to growth signals, which in turn triggers the production of nitric oxide. Nitric oxide widens blood vessels, improves blood flow, and helps new capillaries form. For injured tissue that needs more oxygen and nutrients to heal, this chain of events is significant.
Beyond blood vessel growth, BPC-157 appears to activate fibroblasts, the cells responsible for building collagen and other structural proteins during wound repair. It also shows signs of stabilizing the connection between nerves and muscles, which could matter in injuries where that communication is disrupted. These overlapping effects on blood flow, tissue scaffolding, and nerve signaling are why researchers describe it as acting on multiple healing pathways simultaneously rather than targeting a single mechanism.
Animal Research on Tendons and Muscles
Some of the most compelling animal data involves tendon and muscle healing. In one study, researchers surgically separated the tendon-muscle junction in rat thigh muscles. Untreated rats developed large, persistent defects at the injury site, severe leg contracture, and a tottering walk that never fully resolved. Rats given BPC-157 showed markedly smaller defects from the beginning, and by the end of the study period, the tendon-muscle junction was grossly reestablished.
The differences went beyond appearance. At two weeks, untreated rats still showed significant swelling and inflammation at the injury site, with granulation tissue forming. BPC-157-treated rats had only minimal inflammation and were already rebuilding the structural connection between tendon and muscle. Biomechanical testing confirmed that treated rats recovered full muscle strength, while controls managed only a poor recovery. The treated animals also walked normally, with no contracture.
Gut Protection and Repair
Given its origins in stomach juice, it’s fitting that BPC-157 has been extensively studied for gastrointestinal healing. In rat models of ischemic colitis, where blood flow to a segment of the colon is deliberately cut off, BPC-157 applied locally increased the number of visible blood vessels, preserved the mucosal folds that line the intestine, and dramatically reduced the pale, oxygen-starved areas that indicate tissue damage.
By day 10 of treatment in one model, rats receiving BPC-157 had nearly completely intact mucosa with no gross defects, a normal-diameter colon segment, and only small adhesions. The peptide has been used in early-stage human trials for ulcerative colitis, a chronic inflammatory bowel condition, though detailed results from those trials remain limited. Researchers have described BPC-157 as a “prototype cytoprotective anti-ulcer peptide,” meaning it represents a class of compounds that protect cells from damage and help heal ulcers.
Safety in Animal Studies
One of the more notable findings across BPC-157 research is its apparent lack of toxicity. In studies using both rats and dogs, doses ranging from 6 micrograms per kilogram up to 20 milligrams per kilogram (a roughly 3,000-fold range) were administered by injection over six weeks. Necropsy analysis revealed no adverse changes in the liver, spleen, thymus, or stomach wall at any dose. No toxic or lethal dose was identified across this entire range.
That said, “no toxicity found in animals” is not the same as “proven safe in humans.” Animal safety profiles don’t always translate directly, and the long-term effects of repeated use in people remain unknown. There is no published human toxicology data at scale.
The Current State of Human Evidence
This is where the gap between hype and science is widest. Despite decades of animal research, BPC-157 has very little published human trial data. The most concrete development is a Phase 2 clinical trial (registered as NCT07437547) that began recruiting in early 2026. Sponsored by Hudson Biotech, this randomized, double-blind, placebo-controlled study is testing BPC-157 for acute grade II hamstring strains, the kind of partial muscle tear common in sports.
The trial involves 120 participants receiving either BPC-157 or a placebo for 14 days alongside standard rehabilitation. Researchers are measuring two things: how quickly athletes return to unrestricted sport, and how much the injury shrinks on MRI at day 14. Results are expected by early 2028. Until trials like this produce data, claims about BPC-157’s effectiveness in humans rest on animal studies and anecdotal reports.
Regulatory and Legal Status
BPC-157 is not approved by the FDA or any other major regulatory agency as a drug or supplement for human use. It occupies a gray area: it’s widely sold online, often labeled “for research purposes only,” but is openly purchased and used by consumers. The quality and purity of these products varies, and buyers have no regulatory guarantee that what’s on the label matches what’s in the vial.
For athletes, there’s an additional consideration. The World Anti-Doping Agency (WADA) prohibits all peptides with growth-factor-modulating properties under its banned substance list. Because BPC-157 promotes blood vessel growth and tissue repair through growth factor pathways, it falls under this prohibition. Any athlete subject to anti-doping testing who uses BPC-157 risks a violation, regardless of whether they obtained it legally.
Oral vs. Injectable Forms
BPC-157 is sold in both oral capsules and injectable preparations. Since the peptide was originally isolated from stomach juice, it appears to be unusually stable in acidic environments compared to most peptides, which are quickly broken down by digestive enzymes. This gastric stability is part of why researchers believe oral dosing may be viable, particularly for gut-related conditions where the peptide can act locally on the intestinal lining.
For injuries in muscles, tendons, or joints, injectable forms (typically subcutaneous, meaning just under the skin) are more commonly discussed in the research literature. The logic is straightforward: injecting near the injury site delivers the peptide closer to where it’s needed, bypassing the uncertainty of how much intact peptide reaches distant tissues after oral dosing. However, head-to-head comparisons of oral versus injectable bioavailability in humans have not been published, so the practical difference remains an open question.